Oncolytic Virus Immunotherapy Strategic Research Business Report 2025-2030 Surge in Clinical Trials Combining Oncolytic Viruses With Checkpoint Inhibitors Expands Therapeutic Horizons - ResearchAndMarkets.com
| ONCY Stock | USD 0.88 0.11 11.11% |
Slightly above 62% of Oncolytics Biotech's investor base is looking to short. The analysis of overall sentiment of trading Oncolytics Biotech stock suggests that many investors are alarmed at this time. Oncolytics Biotech's investing sentiment can be driven by a variety of factors including economic data, Oncolytics Biotech's earnings reports, geopolitical events, and overall market trends.
Oncolytics | Build AI portfolio with Oncolytics Stock |
The Oncolytic Virus Immunotherapy - Global Strategic Business Report has been added to ResearchAndMarkets.coms offering. The global market for Oncolytic V...
Read at businesswire.com
 |
Oncolytics Biotech Fundamental Analysis
We analyze Oncolytics Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncolytics Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncolytics Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Oncolytics Biotech is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Oncolytics Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oncolytics Biotech stock to make a market-neutral strategy. Peer analysis of Oncolytics Biotech could also be used in its relative valuation, which is a method of valuing Oncolytics Biotech by comparing valuation metrics with similar companies.
Peers
Oncolytics Biotech Related Equities
| ATYR | ATyr Pharma, | 6.81 | ||||
| SCPH | Scpharmaceuticals | 6.77 | ||||
| IOVA | Iovance Biotherapeutics | 5.60 | ||||
| TRAW | Traws Pharma | 4.11 | ||||
| DMAC | DiaMedica Therapeutics | 2.75 | ||||
| CYCC | Cyclacel Pharmaceuticals | 0.93 | ||||
| VTVT | VTv Therapeutics | 0.75 | ||||
| XERS | Xeris Pharmaceuticals | 1.26 | ||||
| MCRB | Seres Therapeutics | 1.83 |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.